Targovax ASA strengthens management with Lubor Gaal as Chief Financial Officer
Oslo, Norway, 28 February 2022 - Targovax ASA (OSE: TRVX) a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has appointed Dr. Lubor Gaal as Chief Financial Officer (CFO), effective as of 7 March 2022.Dr. Lubor Gaal is a seasoned industry executive with 25 years of experience working in large pharmaceutical and biotechnology companies in Europe and the USA. Most recently, he served as Managing Director and Head of Europe at Locust Walk, a global life science boutique investment bank. At Locust Walk, Dr. Gaal